• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Accord BioPharma Announces New Executive Leadership in Commercialization and Marketing

Article

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care therapies, announced today the hire of several key members of its leadership team: George Esgro Jr. as Senior Vice President of Commercial Operations; Kayla Williams as Executive Director of U.S. Portfolio Strategy and Commercial Development; Nuvan Dassanaike as Senior Vice President of Digital and Marketing Strategy & Operations; and Paul Purdy as Vice President and Head of Market Access. 

George Esgro Jr., a seasoned pharmaceutical industry veteran with experience across various companies including GSK, Amgen, and Roche, joins Accord BioPharma from Ashfield Healthcare, where he served as President of Global Business Development.

With more than 12 years in the pharmaceutical industry, Kayla Williams joins Accord BioPharma from Mylan, where she developed international commercialization strategies for biosimilars in oncology, immunology, and endocrinology.

Nuvan Augustin Dassanaike brings more than 19 years' experience in marketing and digital transformation at global life sciences organizations including Mylan, GSK, ZT Bio Pharma (GNC), and Abbott. Through his digital marketing, innovation, and customer experience leadership, Nuvan has contributed to gains in revenue streams and capturing market share in therapeutic areas such as oncology, respiratory, CNS, and gastroenterology.

During his 30 years of market access experience at companies including GSK, Amgen, and Agios, Paul Purdy has led teams for both market access and sales. He has launched more than 18 products across therapeutic areas such as oncology, endocrinology, rheumatology, neurology, and rare diseases. At Accord BioPharma, Paul will lead a team focused on obtaining access across the payer, distributor and GPO customer channels. 


Recent Videos
Related Content